^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
samatatug zovodotin (XB002)
i
Other names: XB002, ICON-2
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Exelixis
Drug class:
Microtubule inhibitor, Human TF-targeted antibody-drug conjugate
Related drugs:
5ms
Cohort expansion from the phase 1 JEWEL-101 study investigating the tissue factor–targeting antibody-drug conjugate XB002 in patients with advanced solid tumors: Metastatic castration-resistant prostate cancer cohort. (ASCO-GU 2024)
ENA 2022. Clinical trial information: NCT04925284.
Clinical • P1 data • Metastases
|
samatatug zovodotin (XB002)
5ms
Cohort expansion from the phase 1 JEWEL-101 study investigating the tissue factor-targeting antibody-drug conjugate XB002 in patients with advanced solid tumors: Pancreatic and esophageal cancer cohorts. (ASCO-GI 2024)
JEWEL-101 (NCT04925284) is a phase 1, dose-escalation and multi-cohort expansion study evaluating XB002 alone and in combination with nivolumab or bevacizumab in pts with advanced solid tumors. ENA 2022. Clinical trial information: NCT04925284.
Clinical • P1 data • Metastases
|
Opdivo (nivolumab) • Avastin (bevacizumab) • samatatug zovodotin (XB002)
almost2years
Study of XB002 in Subjects With Solid Tumors (JEWEL-101) (clinicaltrials.gov)
P1, N=451, Recruiting, Exelixis | N=199 --> 451
Enrollment change • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HR positive • HER-2 negative • ER negative • PGR negative
|
Opdivo (nivolumab) • samatatug zovodotin (XB002)
Share via
